arrow
C

Clélia Coutzac

centre leon berard
H指数:20
被引数:3,802

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evorpacept plus trastuzumab, ramucirumab and paclitaxel in HER2-positive gastric cancer: a randomized phase 2 trial

Evorpacept联合曲妥珠单抗、雷莫昔单抗和紫杉醇治疗HER2-positive胃癌: 一项随机2期试验

2026-09-240
OAAI
Ivonescimab in combination with chemotherapy in advanced or metastatic gastric cancer (GC) or esophagogastric junction cancer (EGJC): The UCGI 52 – GRACIE trial

伊沃内司单抗联合化疗在晚期或转移性胃癌(GC)或食管胃结合部癌(EGJC)中的应用:UCGI 52 – GRACIE试验

2026-08-300
OAAI
Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial

Ezabenlimab与诱导化疗,随后进行适应性放化疗,用于III期鳞状细胞肛管癌患者的治疗(INTERACT-ION):一项开放标签、单臂、II期临床试验

2025-11-040
OAAI
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial

帕博利珠单抗和伏立诺他联合治疗复发性/转移性鳞状细胞癌的疗效:一项II期篮式试验

2025-06-300
OAAI
Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study

不可切除胰腺癌患者三线化疗疗效的预测因素和预后因素:一项基于队列的研究

2025-06-010
OAAI
BRAF plus EGFR plus /- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer

BRAF V600E突变和错配修复缺陷或微卫星不稳定性高转移性结直肠癌免疫检查点抑制剂后BRAF加EGFR加/- MEK抑制剂

2024-10-012
PRE
Efficacy of immunotherapy in gastro-intestinal (GI) tumors with mismatch repair deficient (MMRd) unusual phenotype

错配修复缺陷(MMRd)异常表型胃肠(GI)肿瘤的免疫疗法疗效

2024-09-011
PRE
Efficacy of surgical gloves (SG) as compression therapy to prevent oxaliplatin-induced peripheral neuropathy (PN): The ELEGANT trial

奥沙利铂诱导性周围神经病变(PN)预防中手术手套(SG)作为加压疗法的疗效:ELEGANT试验

2024-09-010
PRE
IMHOTEP Phase II trial of neoadjuvant pembrolizumab in dMMR/MSI tumors: Results of the colorectal cancer cohort

IMHOTEP II期临床试验:新辅助培美曲塞治疗dMMR/MSI肿瘤的结果——结直肠癌队列

2024-09-011
PRE
Triplet chemotherapy with or without bevacizumab as first line treatment for metastatic colorectal cancer: An AGEO multicenter real-world study

三联化疗加或不加贝伐单抗作为转移性结直肠癌的一线治疗: 一项AGEO多中心真实世界研究

2024-09-010
PRE
IMHOTEP phase II trial of neoadjuvant pembrolizumab in dMMR/MSI localized cancers: Results of the digestive non-colorectal cancer cohorts

IMHOTEP II期临床试验:新辅助培美曲塞在dMMR/MSI局部消化道非结直肠癌队列中的结果

2024-09-010
PRE
Trifluridine/tipiracil plus oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial
2024-08-010
OAAI
Targeted treatment (TT) after immune checkpoint inhibitors (ICIs) in BRAF V600E mutated (BRAFm) and deficient mismatch repair or microsatellite instability high (dMMR/MSI-H) metastatic colorectal cancer (mCRC)
2024-06-010
PRE
PRODIGE 68-UCGI 38-SOREGATT: A randomized phase II study comparing the sequences of regorafenib (reg) and trifluridine/tipiracil (t/t) after failure of standard therapies in patients (pts) with metastatic colorectal cancer (mCRC)
2024-06-010
PRE